CD133 Expression at the Metastatic Site Predicts Patients' Outcome in Colorectal Cancer with Synchronous Liver Metastasis
CD133 Expression at the Metastatic Site Predicts Patients' Outcome in Colorectal Cancer with Synchronous Liver Metastasis
复制标题
DOI：
10.1245/s10434-016-5099-1
复制
发表时间：
2016-06-01
影响因子：
3.7
通讯作者：
Watanabe, Toshiaki
中科院分区：
文献类型：
--
作者：
Kishikawa, Junko;Kazama, Shinsuke;Watanabe, Toshiaki
CD 133是一种跨膜蛋白，被认为是结直肠癌（CRC）的干细胞标志物;然而，CD 133表达与CRC肝转移患者生存率之间的相关性尚未得到充分研究。对88例连续CRC患者的原发肿瘤和同步肝转移瘤中的CD 133表达进行了免疫组化评价，以及这88名患者中27名的残肝中的复发性病变。分析CD 133表达与临床病理特征、无复发生存期和总生存期的关系，88例患者中50例（56.8%）肝转移灶CD 133表达阳性（mCD 133），与原发灶CD 133表达阳性（pCD 133）显著相关（p < 0.001）。肝脏复发性病变中的CD 133表达（recCD 133）也与mCD 133显著相关（p < 0.001）。mCD 133+患者的无病生存期（p = 0.043）和OS（p = 0.014）显著长于mCD 133-患者。此外，mCD 133+患者的肝外复发率显著较低（p < 0.001），肝转移中无CD 133表达的患者的生存期显著较短，这可能是因为mCD 133-患者的肝外复发率显著较高。
CD133 is a transmembrane protein that is proposed to be a stem cell marker of colorectal cancer (CRC); however, the correlation between CD133 expression and survival of CRC patients with liver metastasis has not been fully examined.CD133 expression was evaluated immunohistochemically, both in primary tumors and synchronous liver metastases of 88 consecutive CRC patients, as well as recurrent lesions in the remnant liver of 27 of these 88 patients. The relationship between CD133 expression and clinicopathological characteristics, recurrence-free survival, and overall survival (OS) was analyzed.CD133 expression in liver metastases (mCD133) was detected in 50 of 88 patients (56.8 %), and had significant correlation with CD133 expression in primary lesions (pCD133) (p < 0.001). CD133 expression in liver recurrent lesions (recCD133) also had a significant correlation with mCD133 (p < 0.001). mCD133+ patients had significantly longer disease-free survival (p = 0.043) and OS (p = 0.014) than mCD133- patients. In addition, mCD133+ patients had a significantly lower rate of extrahepatic recurrence (p < 0.001).Patients without CD133 expression in liver metastasis had significantly shorter survival, perhaps because mCD133- patients had a significantly higher rate of extrahepatic recurrence.